摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Tramadol N-Oxide

中文名称
——
中文别名
——
英文名称
Tramadol N-Oxide
英文别名
1-[(1R,2R)-2-hydroxy-2-(3-methoxyphenyl)cyclohexyl]-N,N-dimethylmethanamine oxide
Tramadol N-Oxide化学式
CAS
——
化学式
C16H25NO3
mdl
——
分子量
279.37
InChiKey
HBXKSXMNNGHBEA-ZBFHGGJFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    47.5
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024048A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中POL是聚合物基团,每个Hyp是独立的超支化基团,每个基团SP是独立的间隔基团,每个L是独立的可逆前药连接基团,m为0或1,每个n是独立的整数,范围从2到200,每个x是独立的0或1。此外,还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
  • [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024047A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中B、A和Hyp形成载体,B是一个分支核心,每个A独立地是一条聚乙二醇基聚合链,每个Hyp独立地是一个分支基团,每个SP独立地是一个间隔基团,每个L独立地是一个可逆前药连接基团,每个D独立地是一个生物活性基团,每个x独立地为0或1,每个m独立地是从2到64的整数,n是从3到32的整数;或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物,其用作药物或诊断,以及治疗方法。
  • [EN] RELEASABLE CONJUGATES<br/>[FR] CONJUGUÉS LIBÉRABLES
    申请人:QUIAPEG PHARMACEUTICALS AB
    公开号:WO2018163131A1
    公开(公告)日:2018-09-13
    The present application provides compounds of Formula (B), or pharmaceutically acceptable salts thereof, wherein D is a residue of a biologically active drug, which underdo hydrolysis under physiological conditions to release the biologically active drug and which are useful in the treatment of disorders that could be beneficially treated with the drug.
    本申请提供了化合物的公式(B),或其药用盐,其中D是生物活性药物的残留物,在生理条件下经过水解释放出生物活性药物,并且对可能受益于该药物治疗的疾病具有用处。
  • [EN] PRODRUGS OF HYDROXYL-COMPRISING DRUGS<br/>[FR] PROMÉDICAMENTS DE MÉDICAMENTS COMPRENANT DES GROUPES HYDROXYLE
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013160340A1
    公开(公告)日:2013-10-31
    The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a biologically active moiety-linker conjugate D-L, wherein D is a hydroxyl-comprising biologically active moiety; and L is a promoiety comprising a moiety L1 represented by formula (I) and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer and Z is a carrier group. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
    本发明涉及一种前药或其药学上可接受的盐,包括生物活性基团-连接物D-L的共轭物,其中D是含有羟基的生物活性基团;L是包含由式(I)表示的基团L1的前基团,其中L1被一个到四个基团L2-Z取代,并且可选择进一步取代,前提是式(I)中带星号标记的氢未被取代;其中L2是一个化学键或一个间隔物,Z是一个载体基团。该发明还涉及包含所述前药的药物组合物及其作为药物的用途。
  • PHARAMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY
    申请人:Singh Chandra Ulagaraj
    公开号:US20110039875A1
    公开(公告)日:2011-02-17
    The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and/or a tricyclic antidepressant.
    本发明提供了治疗神经病痛的方法和组合物。在某些实施例中,含有右美沙芬(或其他N-甲基-D-天门冬氨酸受体拮抗剂)、曲马多和加巴喷丁的组合物可以协同作用于人类患者,以减轻疼痛。药物组合物也可以包括辣椒素类、酯化辣椒素类和/或三环抗抑郁剂。
查看更多